Traders should monitor the progress of regulatory approvals and the tender offer, as the deal is expected to close within 90 days. The acquisition significantly strengthens Neurocrine's portfolio in endocrinology and rare disease, with VYKATTM XR providing a durable platform for long-term value creation. The stock may react positively to the deal's closure and any updates on VYKATTM XR's commercial performance under Neurocrine's commercial infrastructure.
Price Chart
Executive Summary
Neurocrine Biosciences (NBIX) has entered into a definitive agreement to acquire Soleno Therapeutics (SLNO) for $53.00 per share in cash, representing a total equity value of $2.9 billion. The acquisition will add VYKATTM XR, the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome, to Neurocrine's portfolio of first-in-class medicines, strengthening its leadership in endocrinology and rare disease. The deal is expected to close within 90 days, subject to customary closing conditions including regulatory approvals.
Key Financial Metrics
Key Facts
- Neurocrine Biosciences is acquiring Soleno Therapeutics for $53.00 per share in cash.
- The total transaction equity value is $2.9 billion.
- The acquisition adds VYKATTM XR, the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome, to Neurocrine's portfolio.
- VYKATTM XR generated $190 million in revenue for Soleno in 2025.
- The deal is expected to close within 90 days, subject to customary closing conditions including regulatory approvals.
- Neurocrine will fund the transaction with cash on hand and plans to take on a modest amount of pre-payable debt.
- Soleno's board of directors recommends that stockholders accept the offer and tender their shares.
- The acquisition strengthens Neurocrine's leadership in endocrinology and rare disease and adds a first-in-class therapy with durable value creation potential.
Financial Impact
The acquisition represents a $2.9 billion equity purchase price, with VYKATTM XR contributing $190 million in 2025 revenue to Soleno. Neurocrine expects the deal to immediately enhance its growth profile and diversify its revenue base.
Risk Factors
- The transaction is subject to customary closing conditions, including regulatory approvals, which could delay or prevent the deal from closing.
- There is uncertainty around how many of Soleno's stockholders will tender their shares in the offer.
- Integration risks and potential disruption to business operations could impact the realization of anticipated benefits.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-142904 |
| Document: d110123dex101.htm | 0001193125-26-142904 |
| Document: d110123d8k.htm | 0001193125-26-142904 |
| Document: d110123dex991.htm | 0001193125-26-142904 |
| Document: d110123dex992.htm | 0001193125-26-142904 |
| Document: 0001193125-26-142904-index-headers.html | 0001193125-26-142904 |
| Document: 0001193125-26-142904-index.html | 0001193125-26-142904 |
| Document: 0001193125-26-142904.txt | 0001193125-26-142904 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $149.50 $139.49 | ▼ −6.70% | ▼ −9.26% | $143.18 (−4.23%) |
Jul 13, 2026 11w ago | Insider Cluster | $174.10 $170.88 | ▼ −1.85% | ▼ −1.06% | $143.18 (−17.76%) |
Jul 9, 2026 12w ago | Press Release | $177.11 $171.55 | ▼ −3.14% | ▼ −2.58% | $143.18 (−19.16%) |
Jun 9, 2026 16w ago | Insider Cluster | $160.86 $156.42 | ▼ −2.76% | ▼ −6.19% | $143.18 (−10.99%) |
Jun 8, 2026 16w ago | Insider Cluster | $165.24 $159.51 | ▼ −3.47% | ▼ −5.88% | $143.18 (−13.35%) |
Jun 8, 2026 16w ago | Insider Cluster | $165.24 $159.51 | ▼ −3.47% | ▼ −5.88% | $143.18 (−13.35%) |
Jun 4, 2026 17w ago | Insider Cluster | $163.88 $159.76 | ▼ −2.51% | ▼ −3.08% | $143.18 (−12.63%) |
Jun 2, 2026 17w ago | Insider Cluster | $164.23 $160.86 | ▼ −2.05% | ▲ +1.77% | $143.18 (−12.81%) |
Jun 2, 2026 17w ago | Insider Cluster | $164.23 $160.86 | ▼ −2.05% | ▲ +1.77% | $143.18 (−12.81%) |
Jun 2, 2026 17w ago | Insider Cluster | $164.23 $160.86 | ▼ −2.05% | ▲ +1.77% | $143.18 (−12.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access